A61K 39/00113
Growth factors
Official title: {Growth factors}
A61K39/00113 (Growth factors) appears on 94 US grants and 199 published applications in this corpus.
Search patents in A61K- Granted patents
- 94
- Published applications
- 199
- Assignees
- 93
- Inventors
- 406
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 3 |
| 2003 | 1 | 3 |
| 2004 | 1 | 6 |
| 2005 | 0 | 3 |
| 2006 | 0 | 8 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 2 | 5 |
| 2010 | 1 | 9 |
| 2011 | 2 | 3 |
| 2012 | 2 | 4 |
| 2013 | 4 | 9 |
| 2014 | 5 | 3 |
| 2015 | 1 | 20 |
| 2016 | 3 | 12 |
| 2017 | 8 | 10 |
| 2018 | 4 | 12 |
| 2019 | 5 | 13 |
| 2020 | 12 | 12 |
| 2021 | 8 | 18 |
| 2022 | 6 | 12 |
| 2023 | 9 | 9 |
| 2024 | 4 | 6 |
| 2025 | 9 | 11 |
| 2026 | 5 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors26 May 2026US 12,636,376 B2
- Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors7 Apr 2026US 12,595,297 B2In3Bio Ltd.
- Engineered T cells31 Mar 2026US 12,590,136 B2Medigene Immunotherapies GmbH
- Compositions and methods for growth factor modulation17 Mar 2026US 12,577,296 B2Scholar Rock, Inc.
- Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF10 Mar 2026US 12,571,027 B2Regeneron Pharmaceuticals, Inc.
- Combinations of cancer therapeutics1 Oct 2026US 2026/0294869 A1Merck Patent GmbH
- Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGF1 Oct 2026US 2026/0297657 A1Regeneron Pharmaceuticals, Inc.
- Tgf-beta-1 vaccine25 Jun 2026US 2026/0176313 A1
- Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors30 Apr 2026US 2026/0115267 A1In3Bio Ltd.
- Compositions and methods for growth factor modulation23 Apr 2026US 2026/0109757 A1Scholar Rock, Inc.
Most cited
By later US patents
- Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof79US 9,572,874 B2CureVac AG · 2017
- Dock-and-lock (DNL) vaccines for cancer therapy68US 7,901,680 B2IBC Pharmaceuticals, Inc. · 2011
- Combination of the application of antibodies for immunostimulation together with glucocorticoids58US 8,709,421 B2Trion Pharma GmbH · 2014
- Methods and compositions for modulating cell proliferation and cell death53US 6,599,912 B12003
- Compositions and methods for growth factor modulation42US 9,573,995 B2Scholar Rock, Inc. · 2017